SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

The single-center, open-label Phase II study has the objective of assess the effect of MD1003 on motor and sensory conduction in patients suffering from demyelinating polyneuropathies in 15 subjects.

Study Overview

• Status: Completed
• Conditions: Charcot-Marie-Tooth Disease; Peripheral Neuropathy; Chronic Inflammatory Demyelinating Polyneuropathy; Charcot-Marie-Tooth Disease Type 1A; Charcot-Marie-Tooth Disease, Type 1B; Anti-MAG Neuropathy
• Intervention / Treatment: Drug: MD1003

• Study Type: Interventional
• Enrollment (Actual): 15
• Phase: Phase 2

Contacts and Locations

Study Locations

• France
  • Creteil, France, 94010
    • Hôpital Henri Mondor, Créteil, France

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male and female aged between 20 and 85 years.
• Patients fulfilling one of the following diagnosis:
• Five patients with chronic inflammatory demyelinating polyneuropathy on both clinical and neurophysiological grounds.
• Five patients with proven genetic diagnosis of CMT1a or CMT1b
• Five patients with anti-MAG polyneuropathy.
• Electrophysiological parameters worsening for the past 3 years
• Available EMG record, performed during the past 6 months to assess variability of NCV parameters
• Signed and dated written informed consent to participate in the study in accordance with local regulations
• Likely to be able to participate in all scheduled evaluation and complete all required study procedures,
• In the opinion of the investigator, the patient will be compliant and have a high probability of completing the study.
• Both male and female subjects who are not either surgically sterile (tubal ligation/obstruction or removal of ovaries or uterus) or post-menopausal (no spontaneous menstrual periods for at least one year confirmed by a negative hormone panel) must commit to using TWO highly effective method of birth control for the duration of the study and for two months after the treatment termination.

Exclusion Criteria:

• Any general chronic handicapping disease other than peripheral neuropathy
• Impossibility to perform the 10 meters walking test
• Impossibility to assess electrophysiological parameters
• Patients with uncontrolled hepatic disorder, renal or cardiovascular disease, or cancer,
• Patients with hypersensitivity to MD1003 excipients (lactose)
• Laboratory tests out of normal range according to the reference laboratory values. Deviations may be accepted if considered by the investigator as not clinically significant with regards to the study continuation,
• Patients with history or presence of alcohol abuse or drug addiction,
• Patients likely to be non-compliant to the study procedures or for whom a long-term follow-up seems to be difficult to achieve.
• Any new medication for neuropathy initiated less than 3 months prior to inclusion. For CIDP patients, relapse in the past 3 months before inclusion.
• Not easily contactable by the investigator in case of emergency or not capable to call the investigator
• Subjects without effective contraception

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MD1003; MD1003 100mg capsules, 1 capsule tid for 48 weeks	Drug: MD1003; Other Names: High Dose Biotin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Motor Nerve Conduction Velocity (m/Sec)	Absolute change from baseline at Week 48.	48 weeks
Distal Latency (Msec)	Absolute change from baseline at Week 48.	48 weeks
F Wave Latency (Msec)	Absolute change from baseline at Week 48.	48 weeks
Length of Motor Nerve Potential	Absolute change from baseline at W48.	48 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ONLS (Overall Neuropathy Limitations Scale)	The ONLS focuses on upper and lower limb functions, and consists of a checklist for interviewing patients. It is scored from 0 to 5 on the upper limb section and from 0 to 7 on the lower limb section. A score of 0 indicates no limitations (the ceiling of the scale) and a score of 5 or 7 indicates no purposeful movement. Absolute change from baseline at week 48.	48 weeks
Change From Baseline at Week 48 for Timed 10-meter Walk Test	Absolute change from baseline at week 48. The patient is instructed to walk at normal pace for 10 meters. Start and stop of performance time coincides with the toes of the leading foot crossing the 2-m mark and the 8-m mark, respectively. From these data, the speed may be calculated by dividing the middle 6 m by the time (in seconds).	48 weeks
Absolute Change From Baseline at Week 48 for Medical Research Council (MRC) Subscore (Total Muscle) and Total Score	MRC score assessed in 19 muscles. The muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle. The patient's effort is graded on a scale of 0-5: Grade 5: Muscle contracts normally against full resistance. Grade 4: Muscle strength is reduced but muscle contraction can still move joint against resistance. Grade 3: Muscle strength is further reduced such that the joint can be moved only against gravity with the examiner's resistance completely removed. As an example, the elbow can be moved from full extension to full flexion starting with the arm hanging down at the side. Grade 2: Muscle can move only if the resistance of gravity is removed. As an example, the elbow can be fully flexed only if the arm is maintained in a horizontal plane. Grade 1: Only a trace or flicker of movement is seen or felt in the muscle or fasciculations are observed in the muscle. Grade 0: No movement is observed.	48 weeks
INCAT Sensory Sum Score (ISS)	This sensory scale comprises pin prick and vibration sense plus a two point discrimination value in the arms and legs, and ranges from 0 ("normal sensation") to 20 ("most severe sensory deficit"). Absolute change from baseline at week 48.	48 weeks
6-minute Walk Test	The 6MWT is a practical simple test that requires a 30 m (100-ft) hallway. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. Absolute change from baseline at week 48.	48 weeks
Posturography Score	Computerized dynamic posturography (CDP) is a non-invasive specialized clinical assessment technique used to quantify the central nervous system adaptive mechanisms (sensory, motor and central) involved in the control of posture and balance, both in normal and abnormal conditions. Absolute change of speed in spontaneous speed condition from baseline at week 48.	48 weeks
Excitability Testing: Supernormality (%)	Nerve excitability testing is a non-invasive approach in investigating the pathophysiology of peripheral nerve disorders, which determines the electrical properties of the nerve membrane at the site of stimulation. Absolute change from baseline at week 48. After a nerve fiber is depolarized, a sequence of excitability changes, called the 'recovery cycle', occurs before the membrane potential returns to its resting stage. This cycle includes phases in which the nerve excitability is decreased ('refractory period' or increased ('supernormal period'). During the 10-30 ms following the end of the refractory period, the axon increases its excitability and the nerve fiber is more easily excited (the supernormal period). Depolarization of the node of Ranvier excites the adjacent internodes, which then charge with electric current as capacitors. Supernormality depends on many factors and its interpretation is therefore not univoqual. Data were provided for information only.	48 weeks
Strength-duration Time Constant (ms)	This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline at week 48. Strength-duration Time Constant (ms) is a measurement of excitability, defined as the duration of the stimulus that has twice the strength of the rheobase current (see below). The lower the rheobase is, the higher is the Strenght duration time constant. Accordingly, higer values of SDTC are associated with better outcome.	48 weeks
Rheobase (mA)	This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline at week 48. Rheobase is the minimal strength of an electrical stimulus of infinitely long duration that is able to cause excitation. Low values are associated with better outcome (the nerve becomes more excitable).	48 weeks
Refractoriness (%)	This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline to week 48. After a nerve fiber is depolarized, a sequence of excitability changes, called the 'recovery cycle', occurs before the membrane potential returns to its resting stage. This cycle includes phases in which the nerve excitability is decreased ('refractory period' or increased ('supernormal period'). Refractoriness depends on many factors and its interpretation is therefore not univoqual. Data were provided for information only.	48 weeks
Minimum Absolute Refractory Period (ms).	This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline at week 48. After a nerve fiber is depolarized, a sequence of excitability changes, called the 'recovery cycle', occurs before the membrane potential returns to its resting stage. This cycle includes phases in which the nerve excitability is decreased ('refractory period' or increased ('supernormal period'). Refractoriness depends on many factors and its interpretation is therefore not univoqual. Data were provided for information only.	48 weeks
Maximum Absolute Refractory Period (ms).	This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline at week 48. After a nerve fiber is depolarized, a sequence of excitability changes, called the 'recovery cycle', occurs before the membrane potential returns to its resting stage. This cycle includes phases in which the nerve excitability is decreased ('refractory period' or increased ('supernormal period'). Refractoriness depends on many factors and its interpretation is therefore not univoqual. Data were provided for information only.	Week 48

Collaborators and Investigators

• Sponsor: MedDay Pharmaceuticals SA
• Investigators: Principal Investigator: Alain CREANGE, MD, Hôpital Henri Mondor, Créteil, France; Study Director: Frederic Sedel, MD, Medday Pharmaceuticals

Publications and helpful links

Helpful Links

• Sponsor

Study record dates

Study Major Dates

• Study Start (Actual): December 5, 2016
• Primary Completion (Actual): March 18, 2019
• Study Completion (Actual): March 18, 2019

Study Registration Dates

• First Submitted: November 8, 2016
• First Submitted That Met QC Criteria: November 15, 2016
• First Posted (Estimate): November 18, 2016

Study Record Updates

• Last Update Posted (Actual): November 2, 2020
• Last Update Submitted That Met QC Criteria: October 29, 2020
• Last Verified: October 1, 2020

More Information

Terms related to this study

• Keywords: Neuropathy; Demyelinating polyradiculoneuropathy
• Additional Relevant MeSH Terms: Nervous System Diseases; Immune System Diseases; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Autoimmune Diseases; Congenital Abnormalities; Genetic Diseases, Inborn; Neuromuscular Diseases; Stomatognathic Diseases; Neurodegenerative Diseases; Heredodegenerative Disorders, Nervous System; Nervous System Malformations; Polyradiculoneuropathy; Peripheral Nervous System Diseases; Polyneuropathies; Tooth Diseases; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Nerve Compression Syndromes; Charcot-Marie-Tooth Disease; Hereditary Sensory and Motor Neuropathy; Physiological Effects of Drugs; Micronutrients; Vitamins; Vitamin B Complex; Biotin
• Other Study ID Numbers: MD1003CT2015-01 SERENDEM

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No